New drug combo shows promise against childhood cancer
Disease control
Recruiting now
This study tests whether adding an antibody drug called hu14.18K322A to standard chemotherapy helps children with high-risk neuroblastoma, a rare but aggressive childhood cancer. About 144 children and teens aged 18 months to 18 years will receive the combination over up to 12 cy…
Phase: PHASE2, PHASE3 • Sponsor: Renaissance Pharma Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC